Other new interesting classes of drugs under investigation against DLBCL include mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) inhibitors (e.g., safimaltib and ABBV-525), interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors (e.g., emavusertib) and macrophage checkpoint inhibitors (e.g., magrolimab, lemzoparlimab, and evorpacept) [187]. This evidence concerns the gene IRAK4 and diffuse large B-cell lymphoma.